Table 1.
Group | d 0 | d 1 | d 2 | d 3 | d 4 | d 5 | d 6 | d 7 | d 8 | d 9 | d 10 | d 11 | d 12 | d 13 | d 14 | d 15 | d 16 | |
3 TIW | 9 | - | 3 | - | 3 | - | - | 3 | - | 3 | - | 3 | - | - | 3 | - | 3 | 3 TIW until wk 48 |
3 Q2D | 9 | - | 3 | - | 3 | - | 3 | - | 3 | - | 3 | - | 3 | - | 3 | - | 3 | 3 Q2D until wk 48 |
3 QD | 9 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | - | 3 | |
9 QD | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | - | 3 |
All patients received a first dose of 9 Mega units (MU) of IFN-α. Group “3 TIW” received 3 MU doses of IFN-α three times a week until wk 48; group “3 Q2D” received 3 MU doses of IFN-α every other day; group “3 QD” received 3 MU daily after the first dose until d 14, followed by 3 MU every other day until wk 48; group “9 QD” received 9 MU daily after the first dose until d 14, followed by 3 MU every other day until wk 48. All groups received two doses of 500 mg ribavirin daily for 48 wk. -:Interferon was not administered that day.